Anastasia Prokopi

Anastasia Prokopi

Auto-generated profile, based on publicly available information

Anastasia Prokopi

Faculty of Medicine and Dentistry, Centre for Clinical Pharmacology and Precision Medicine, William Harvey Research Institute, Queen Mary University of London

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2021 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
APAnastasia Prokopi
Anastasia Prokopi
CTChristoph Heinrich Tripp
Christoph Heinrich Tripp
BTBart Tummers
Bart Tummers
FHFlorian Hornsteiner
Florian Hornsteiner
SSSarah Spoeck
Sarah Spoeck
PSPatrizia Stoitzner
Patrizia Stoitzner
Background Immunotherapy with checkpoint inhibitors has shown impressive results in patients with melanoma, but still many do not benefit from this line of treatment. A lack of tumor-infiltrating T cells is a common reason for therapy failure but also a loss of intratumoral dendritic cells (DCs) has been described. Methods We used the transgenic tg(Grm1)EPv melanoma mouse strain that develops spontaneous, slow-growing tumors to perform immunological analysis during tumor progression. With flow cytometry, the frequencies of DCs and T cells at different tumor stages and the expression of the inhibitory molecules programmed cell death protein-1 (PD-1) and T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) on T cells were analyzed. This was complemented with RNA-sequencing (RNA-seq) and real-time quantitative PCR (RT-qPCR) analysis to investigate the immune status of the tumors. To boost DC numbers and function, we administered Fms-related tyrosine 3 ligand (Flt3L) plus an adjuvant mix of polyI:C and anti-CD40. To enhance T cell function, we tested several checkpoint blockade antibodies. Immunological alterations were characterized in tumor and tumor-draining lymph nodes (LNs) by flow cytometry, CyTOF, microarray and RT-qPCR to understand how immune cells can control tumor growth. The specific role of migratory skin DCs was investigated by coculture of sorted DC subsets with melanoma-specific CD8+ T cells. Results Our study revealed that tumor progression is characterized by upregulation of checkpoint molecules and a gradual loss of the dermal conventional DC (cDC) 2 subset. Monotherapy with checkpoint blockade could not restore antitumor immunity, whereas boosting DC numbers and activation increased tumor immunogenicity. This was reflected by higher numbers of activated cDC1 and cDC2 as well as CD4+ and CD8+ T cells in treated tumors. At the same time, the DC boost approach reinforced migratory dermal DC subsets to prime gp100-specific CD8+ T cells in tumor-draining LNs that expressed PD-1/TIM-3 and produced interferon γ (IFNγ)/tumor necrosis factor α (TNFα). As a consequence, the combination of the DC boost with antibodies against PD-1 and TIM-3 released the brake from T cells, leading to improved function within the tumors and delayed tumor growth. Conclusions Our results set forth the importance of skin DC in cancer immunotherapy, and demonstrates that restoring DC function is key to enhancing tumor immunogenicity and subsequently responsiveness to checkpoint blockade therapy.

8 November 2019 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
LBLydia Bellmann
Lydia Bellmann
GCGiuseppe Cappellano
Giuseppe Cappellano
JSJohanna F. Schachtl‐Riess
Johanna F. Schachtl‐Riess
APAnastasia Prokopi
Anastasia Prokopi
ASAthanasios Seretis
Athanasios Seretis
PSPatrizia Stoitzner
Patrizia Stoitzner
Therapeutic success of targeted therapy with BRAF inhibitors (BRAFi) for melanoma is limited by resistance development. Observations from preclinical mouse models and recent insights into the immunological effects caused by BRAFi give promise for future development of combination therapy for human melanoma. In our study, we used the transplantable D4M melanoma mouse model with the BRAFV600E mutation and concomitant PTEN loss in order to characterize alterations in tumor‐infiltrating effector immune cells when tumors become resistant to BRAFi. We found that BRAFi‐sensitive tumors displayed a pronounced inflammatory milieu characterized by high levels of cytokines and chemokines accompanied by an infiltration of T and NK cells. The tumor‐infiltrating effector cells were activated and produced high levels of IFN‐γ, TNF‐α and granzyme B. When tumors became resistant and progressively grew, they reverted to a low immunogenic state similar to untreated tumors as reflected by low mRNA levels of proinflammatory cytokines and chemokines and fewer tumor‐infiltrating T and NK cells. Moreover, these T and NK cells were functionally impaired in comparison to their counterparts in BRAFi‐sensitive tumors. Their effector cell function could be restored by additional peritumoral treatment with the TLR7 agonist imiquimod, a clinically approved agent for nonmelanoma skin cancer. Indeed, resistance to BRAFi therapy was delayed and accompanied by high numbers of activated T and NK cells in tumors. Thus, combining BRAFi with an immune stimulating agent such as a TLR ligand could be a promising alternative approach for the treatment of melanoma.

9 January 2022 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
LBLydia Bellmann
Lydia Bellmann
HSHelen Strandt
Helen Strandt
CZClaudia Zelle‐Rieser
Claudia Zelle‐Rieser
DODaniela Ortner-Tobider
Daniela Ortner-Tobider
CTChristoph Heinrich Tripp
Christoph Heinrich Tripp
PSPatrizia Stoitzner
Patrizia Stoitzner
Human skin is a preferred vaccination site as it harbors multiple dendritic cell (DC) subsets, which display distinct C‐type lectin receptors (CLR) that recognize pathogens. Antigens can be delivered to CLR by antibodies or ligands to boost antigen‐specific immune responses. This concept has been established in mouse models but detailed insights into the functional consequences of antigen delivery to human skin DC in situ are sparse. In this study, we cloned and produced an anti‐human Langerin antibody conjugated to the EBV nuclear antigen 1 (EBNA1). We confirmed specific binding of anti‐Langerin‐EBNA1 to Langerhans cells (LC). This novel LC‐based vaccine was then compared to an existing anti‐DEC‐205‐EBNA1 fusion protein by loading LC in epidermal cell suspensions before coculturing them with autologous T cells. After restimulation with EBNA1‐peptides, we detected elevated levels of IFN‐γ‐ and TNF‐α‐positive CD4+ T cells with both vaccines. When we injected the fusion proteins intradermally into human skin explants, emigrated skin DC targeted via DEC‐205‐induced cytokine production by T cells, whereas the Langerin‐based vaccine failed to do so. In summary, we demonstrate that antibody‐targeting approaches via the skin are promising vaccination strategies, however, further optimizations of vaccines are required to induce potent immune responses.

30 June 2026 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
SDSophie Dieckmann
Sophie Dieckmann
CTChristoph Heinrich Tripp
Christoph Heinrich Tripp
HSHelen Strandt
Helen Strandt
FHFlorian Hornsteiner
Florian Hornsteiner
ASAnnelie Kerstin Schäfer
Annelie Kerstin Schäfer
PSPatrizia Stoitzner
Patrizia Stoitzner
Background: Metabolic competition and nutrient restriction in the tumor microenvironment (TME) shape the immune infiltrate in tumors and subsequently tumor immunity. In this study we used the transgenic melanoma mouse model tg(Grm1)EPv, which spontaneously develops melanoma due to the ectopic expression of the metabotropic glutamate receptor 1 ( Grm1 ) in melanocytes to investigate if aberrant glutamate metabolism drives tumor formation and affects immune cell function. Methods: We performed liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based metabolomic analyses and RNA sequencing on tumor-free and tumor-bearing tg(Grm1)EPv tissues to characterize metabolic alterations associated with tumor progression. Flow cytometry was used to examine changes in immune cell subsets within the TME. To assess the functional relevance of glutamate metabolism, we inhibited glutathione metabolism using L-buthionine-(S,R)-sulfoximine (BSO), an inhibitor of glutamate-cysteine ligase that depletes cellular glutathione levels. Results: LC-MS/MS-based metabolomic analyses and RNA sequencing revealed changes in glutamate and glutamine metabolism, a glycolytic shift (Warburg effect), and reduced ATP levels in advanced tumors compared with tumor-free tissue, suggesting respiratory chain dysfunction. These metabolic changes in the TME are advantageous for the tumor cells and unfavorable for immune cells, such as dendritic cells (DC). Indeed, flow cytometry analysis of myeloid subsets during tumor progression showed a decline in tumor-infiltrating conventional type 2 DC and macrophages, alongside an increase in neutrophil and monocyte populations in advanced lesions. Interference with glutamate metabolism using BSO induced immunogenic cell death, namely ferroptosis, in an tg(Grm1)EPv-derived cell line in vitro. Therefore, we evaluated the combination of this inhibitor with immunotherapy as a promising new approach for the treatment of tumors in the tg(Grm1)EPv mouse model. We observed that tumor growth could be delayed in vivo when BSO was combined with a therapy regimen boosting DC numbers and activation. This inhibition of tumor growth was supported by the infiltration of activated T cells. Conclusion: Overall, our findings provide novel insights into the importance of combining metabolic intervention with immunotherapy for the treatment of patients with melanoma, particularly those bearing glutamate pathway-active or immunologically cold tumors. This knowledge can drive the design of novel therapeutic strategies for patients with cancer.

31 July 2026 in medRxiv
Verified
Preprint
Open access
PDF file
CDClaire Duperrex
Claire Duperrex
GSGemma Smith
Gemma Smith
CCChristophe Clesse
Christophe Clesse
ODOlivier Duperrex
Olivier Duperrex
SRSimone Rahman
Simone Rahman
LCLivia Carvalho
Livia Carvalho
Introduction: Depression is common among people receiving haemodialysis and is associated with adverse outcomes, but the biological pathways underlying this relationship remain uncertain. We examined associations between depressive symptoms, mortality, immune–metabolic markers and stress-related transcriptional profiles, including potential sex differences in routine biomarkers. Methods: We studied 297 adults receiving maintenance haemodialysis across North and East London and Essex. Moderate/severe depressive symptoms were defined as a 17-item Hamilton Depression Rating Scale score >18. Cox regression examined all-cause mortality from enrolment until death or administrative censoring on 24 March 2026. Linear regression assessed associations between depressive-symptom severity and routinely measured immune–metabolic markers, overall and by sex. In a laboratory subset, inflammatory proteins and transcriptional profiles were examined overall only. Results: Moderate/severe depressive symptoms were associated with higher mortality in the adjusted model, although the association was attenuated after full adjustment (hazard ratio, 1.49; 95% confidence interval, 1.00–2.23; P=0.052). Higher white-cell count was associated with greater depressive-symptom severity before, but not after, adjustment for body mass index. Diastolic blood pressure was the only routine marker showing evidence that its association with depressive symptoms differed by sex (interaction P=0.022). Exploratory analyses did not provide convincing evidence that the measured biomarkers accounted for the depression–mortality association. In the laboratory subset, no inflammatory protein or transcriptional measure was significantly associated with depressive symptoms in fully adjusted analyses. Conclusion: Depression may identify a clinically relevant risk state among people receiving haemodialysis. The exploratory biological findings require validation in larger, prospectively sampled cohorts.